Transcode Research Development from 2010 to 2026

RNAZ Stock  USD 8.01  0.08  1.01%   
Transcode Therapeutics Research Development yearly trend continues to be fairly stable with very little volatility. Research Development will likely drop to about 5.6 M in 2026. During the period from 2010 to 2026, Transcode Therapeutics Research Development regression line of annual values had r-squared of  0.59 and arithmetic mean of  3,102,867. View All Fundamentals
 
Research Development  
First Reported
2019-12-31
Previous Quarter
2.6 M
Current Value
3.2 M
Quarterly Volatility
1.2 M
 
Covid
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 315.4 K, Interest Expense of 29.3 K or Selling General Administrative of 6.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Transcode Stock
Check out the analysis of Transcode Therapeutics Correlation against competitors.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Latest Transcode Therapeutics' Research Development Growth Pattern

Below is the plot of the Research Development of Transcode Therapeutics over the last few years. It is Transcode Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Transcode Research Development Regression Statistics

Arithmetic Mean3,102,867
Geometric Mean466,440
Coefficient Of Variation149.65
Mean Deviation3,909,045
Median82,532
Standard Deviation4,643,414
Sample Variance21.6T
Range12.2M
R-Value0.77
Mean Square Error9.4T
R-Squared0.59
Significance0.0003
Slope705,899
Total Sum of Squares345T

Transcode Research Development History

20265.6 M
202511.1 M
20249.6 M
202312.3 M
202210.2 M
20212.8 M
2020284.5 K

About Transcode Therapeutics Financial Statements

Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development11.1 M5.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.